Natco Pharma's Ozempic Generic Launches at ₹1,290 in India

A New Chapter for Diabetes Care in India

Hyderabad-based Natco Pharma Ltd. has initiated a significant shift in India's diabetes and weight-loss drug market by launching its generic version of semaglutide. The launch, strategically timed for March 21, 2026, occurred just one day after the key patent held by Danish pharmaceutical giant Novo Nordisk A/S expired. This move is set to dramatically increase access to the highly effective GLP-1 agonist therapy, which has seen soaring global demand under brand names like Ozempic and Wegovy.

Natco's entry is marked by an aggressive pricing strategy, positioning its product as the most affordable option in the country. This development is poised to trigger a price war among domestic drugmakers, fundamentally altering the treatment landscape for millions of patients with Type 2 diabetes and obesity in India.

Aggressive Pricing and Innovative Formulation

Natco Pharma is introducing its generic semaglutide under the brand names SEMANAT and SEMAFULL. The company's primary strategy revolves around a multi-dose vial format, a first for semaglutide in India. This format significantly lowers production and packaging costs, allowing for a disruptive market entry price. The monthly cost for the vial starts at ₹1,290 for the 2mg/1.5ml and 4mg/3ml strengths, and ₹1,750 for the higher 8mg/3ml strength.

This pricing represents a staggering 90% reduction compared to the innovator brand's cost, which often exceeded ₹10,000 per month. The company stated that its vial format is approximately 70% cheaper than the pen injector devices commonly used for this class of drugs. Recognizing patient preference for convenience, Natco also plans to launch a pen device version in April 2026, with prices ranging from ₹4,000 to ₹4,500 per month, which is still substantially lower than the original product.

The Patent Cliff and Market Competition

The launch was made possible by the expiration of Novo Nordisk's patent on the semaglutide molecule in India on March 20, 2026. This event, often referred to as a "patent cliff," has opened the floodgates for generic competition. It is estimated that over 40 Indian pharmaceutical companies are preparing to introduce their own versions of semaglutide, creating a highly competitive environment. While many competitors are expected to price their products in the ₹3,000 to ₹5,000 range, Natco's sub-₹1,300 entry point sets a new, low benchmark that others will be forced to address.

This impending competition had already prompted Novo Nordisk to reduce the price of Ozempic by up to 37% in late 2025, but generic alternatives are set to drive costs down even further, benefiting a large patient population that previously found the treatment unaffordable.

Regulatory Path and Strategic Partnerships

Natco Pharma's market entry was preceded by regulatory clearance from the Central Drugs Standard Control Organisation (CDSCO) in February 2026. The approval was granted after the company successfully completed a clinical comparison study, ensuring its generic product's efficacy and safety are comparable to the original. The approval covers both the multi-dose vials and the upcoming pen devices.

To maximize its reach, Natco is not only relying on its own distribution network but is also pursuing co-marketing agreements. The company has already signed a distribution pact with Eris Lifesciences to market the therapy across India. This strategy allows Natco to leverage the established sales and distribution channels of its partners, ensuring wider availability of its affordable semaglutide products, including in smaller towns and cities.

Product and Pricing Summary

To provide clarity on Natco's offerings, the following table outlines the product details and pricing structure:

Market and Investor Reaction

The announcement was met with a positive response from the market. On the day of the announcement, Natco Pharma's shares traded higher, gaining nearly 3% to reach ₹963. This reflects investor confidence in the company's ability to capture a significant share of the burgeoning market for GLP-1 drugs in India. The launch is seen as a major growth driver for Natco, leveraging its strengths in generic manufacturing and strategic pricing.

Conclusion: A Paradigm Shift in Treatment Access

Natco Pharma's launch of generic semaglutide at a fraction of the original cost marks a pivotal moment for healthcare in India. By making this advanced therapy for Type 2 diabetes and obesity management more affordable, the company is addressing a critical unmet need in a country with a high prevalence of these conditions. The move is expected to significantly improve treatment adherence and long-term health outcomes for countless patients. As competition intensifies, prices are likely to fall further, solidifying a new era of accessibility for this important class of medication.